The effect of GSK2190915, a 5-lipoxygenase activating protein inhibitor, on the early asthmatic response to inhaled allergen Source: Annual Congress 2011 - Asthma management and response Year: 2011
The effect of GSK2190915, a 5-lipoxygenase activating protein inhibitor, on the allergen induced asthmatic response Source: Annual Congress 2011 - New treatments for airway disease Year: 2011
Assessment of in vivo 5-lipoxygenase (5-LO) activity in nonatopic and atopic subjects with or without asthma: effects of treatment with the 5-LO inhibitor zileuton Source: Eur Respir J 2003; 22: Suppl. 45, 101s Year: 2003
Inhibition of eosinophil migration by montelukast, a cysteinyl leukotriene receptor antagonist, through down regulation of plasmin activity Source: Eur Respir J 2004; 24: Suppl. 48, 36s Year: 2004
Involvement of 5-lipoxygenase (5-LO) pathway in eosinophil chemotaxis to acetylsalicylic acid (ASA) in aspirin-sensitive and healthy non-allergic subjects Source: Eur Respir J 2002; 20: Suppl. 38, 382s Year: 2002
The CysLT1 receptor antagonist montelukast inhibits mast cell activation induced by inhaled leukotriene E4 in subjects with asthma Source: International Congress 2016 – Clinical and molecular studies in asthma Year: 2016
The effects of a cysteinyl leukotriene receptor antagonist, pranlukast, on dendritic cell chemoattractants in the airways of subjects with asthma Source: Eur Respir J 2004; 24: Suppl. 48, 132s Year: 2004
Higher expression of lipoxygenase and cyclooxygenase pathways in bronchial than alveolar lavage from allergic asthmatics Source: Virtual Congress 2021 – Clinical features and new biomarkers of asthma, COPD and chronic cough Year: 2021
Elevated IL-10 level but not cysteinyl leukotrienes (CysLT) release from leukocytes in vitro correlates with good response to treatment with montelukast in asthmatic patients Source: International Congress 2014 – Asthma and COPD management Year: 2014
The effect of a leukotriene antagonist, pranlukast, on allergen-induced airway responses and circulating dendritic cells in subjects with atopic asthma Source: Eur Respir J 2003; 22: Suppl. 45, 414s Year: 2003
The pro-apoptotic effect of cysteinyl leukotriene receptor (CysLT-R) antagonist montelukast is mediated by CysLT-Rs expression on antigen-stimulated T cells Source: Eur Respir J 2003; 22: Suppl. 45, 100s Year: 2003
Interactive inhibitory effects of formoterol and montelukast on activated human neutrophils Source: Eur Respir J 2010; 36: 1417-1424 Year: 2010
Do leukotriene antagonists reduce eosinophil numbers in induced sputum from asthmatic patients as a consequence of increased apoptosis induction? Source: Eur Respir J 2002; 20: Suppl. 38, 584s Year: 2002
Down-regulation of SLPI by cysteinyl leukotrienes in human bronchial epithelial cells can be reverted by glucocorticoids Source: Annual Congress 2011 - Lung cell injury and repair Year: 2011
Differential actions of phosphatidyinositol 3-kinase inhibitors on respiratory burst and leukotriene C4 generation in PAF-stimulated human eosinophils Source: Eur Respir J 2003; 22: Suppl. 45, 547s Year: 2003
Role of lipoxin A4 in induced sputum of asthmatic children Source: Annual Congress 2008 - Invasive and noninvasive measurements of lung inflammation Year: 2008
Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459 Source: Eur Respir J 2013; 41: 46-52 Year: 2013
Upregulation of cysteinyl leukotriene receptors CysLT1 and CysLT2 by TGF-β1 and LTE4 on human bronchial epithelial cells Source: Annual Congress 2006 - Airway epithelial cells in inflammation Year: 2006
Dissociation of airway inflammation and hyperresponsiveness by cyclooxygenase inhibition in allergen challenged mice Source: Eur Respir J 2009; 34: 200-208 Year: 2009
Inhibition of mast cell PGD2 release protects against mannitol-induced airway narrowing Source: Eur Respir J 2006; 27: 944-950 Year: 2006